Newer Medicines 1 - 10

1. Aliskiren: Renin Inhibitor

2. Ambrisentan: Endothelin receptor antagonist for treatment of pulmonary hypertension.

3. Anidulafungin: Echinocandin antifungal for treatment of candidemia, abcess, oesophagial candidasis.

4. Armodafinil : CNS stimulant, R-enantiomer of Modafinil

5. Atomoxetine: CNS noradrenaline (NA) reuptake inhibitor, first and only FDA approved non-stimulant drug for treatment of ADHD.

6. Bosentan: Endothelin-1-Antagonist, Cardiac remodeling inhibitor. Used for Rx of PPH.

7. Candoxatrilat: Inhibit Neutral Endopeptidase, increases ANP.

8. Carperitide: Recombinant BNP.

9. Cinacalcet - Cinacalcet is an oral calcimimetic agent that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium. The calcium-sensing receptors on the surface of parathyroid gland cells also regulate parathyroid hormone (PTH) secretion. Increasing the sensitivity of these receptors results in lowering of PTH which subsequently lowers serum calcium levels. In addition, significant reductions in calcium may lower the threshold for seizures. Sensipar is an oral calcimimetic medication that lowers the levels of parathyroid hormone, phosphurous and calcium in patients undergoing kidney dialysis or in patients with parathroid cancer. Cinacalcet (Senipar) is indicated for the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis and the treatment of elevated calcium levels (hypercalcemia) in patients with parathyroid carcinoma. The recommended starting oral dose of Sensipar is 30 mg once daily.

10. Conivaptan is a non-peptide dual arginine vasopressin (AVP) V1A and V2 receptor antagonist. It is designed to inhibit the effects of AVP, also known as antidiuretic hormone (ADH), is specifically indicated for the treatment of SIADH. . In the kidneys, AVP's activity (primarily at V2 receptors) inhibits aquaresis, or excretion of free water. By exerting antagonistic activity at both V1A and V2 receptors, the drug is designed to inhibit inappropriate/excessive AVP secretion, thereby increasing rates aquaresis. Increased water secretion is correlated with net fluid loss, increased urinary output, and decreased urinary osmolality. Can cause hypokalemia, edema, pollakuria(daytime excessive urination)


pgmeedoubts@gmail.com